[Lamotrigine in women with epilepsy. Review of present data].
The manuscript deals with the tolerability of Lamotrigine in women. The recent literature is reviewed with respect to interactions with oral contraceptives, sexuality, infertility, interactions with sex hormones, polycystic ovarian syndrome, adipositas, cosmetic side effects, osteoporosis, pregnancy, breast feeding, and teratogenetic effects. The available data have practical implications for the safe use of Lamotrigine in women.
Schmitz
B
B
Neurologische Klinik und Poliklinik der Charité, Campus Virchow-Klinikum, Humboldt-Universität Berlin, Berlin. bettina.schmitz@charite.de
D000014:Abnormalities, Drug-Induced / Q000097:blood / Q000209:etiology*; D000927:Anticonvulsants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood / Q000139:chemically induced*; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000097:blood / Q000139:chemically induced*; D000077213:Lamotrigine; D008657:Metabolic Clearance Rate / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000139:chemically induced*; D011247:Pregnancy; D014227:Triazines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000927:Anticonvulsants; D003276:Contraceptives, Oral; D012739:Gonadal Steroid Hormones; D014227:Triazines; D000077213:Lamotrigine